Hester Biosciences Ltd
Thu 13/03/2025,15:53:17 | NSE : HESTERBIO
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1287.60
Previous Close
₹ 1281.15
Volume
26468
Mkt Cap ( Rs. Cr)
₹1150.47
High
₹ 1378.25
Low
₹ 1275.00
52 Week High
₹ 3379.00
52 Week Low
₹ 1252.70
Book Value Per Share
₹ 354.81
Dividend Yield
0.44
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Hester Biosciences Ltd
Your Vote -
Buy
88.89%
Hold
2.78%
Sell
8.33%
88.89%
36 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
1352.40
42
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
42
Option Chain
Analyzes market sentiment, predicts Hester Biosciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Hester Biosciences L - Intimation Of Shifting Of The Registered Office Of The Company
-
Hester Biosciences L - Address Change
-
Hester Biosciences L - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Hester Biosciences L - Shareholders meeting
-
Hester Biosciences L - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Hester Biosciences L - Integrated Filing- Governance
-
Hester Biosciences L - Integrated Filing (Governance) For The Quarter Ended 31 December 2024
-
Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Hester Biosciences L - Copy of Newspaper Publication
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates
-
Hester Biosciences L - Integrated Filing- Financial
-
Hester Biosciences L - Press Release
-
Hester Biosciences L - Financial Result Updates
-
Hester Biosciences L - Outcome of Board Meeting
-
Hester Biosciences L Q3 net profit down 31.48% at Rs 4.44 cr
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Hester Biosciences L - Integrated Filing (Financial)
-
Hester Biosciences L - Board Meeting Outcome for Outcome Of Board Meeting Held On 30 Janauary 2025
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates
-
Hester Biosciences L - Board Meeting Intimation
-
Hester Biosciences L - Board Meeting Intimation for Financial Results
-
Hester Biosciences L - Action(s) initiated or orders passed
-
Hester Biosciences L - Intimation Regarding Receipt Of Order From GST Department, Panchkula (Haryana)
-
Hester Biosciences L - Copy of Newspaper Publication
-
Hester Biosciences L - Notice Of Shareholders Meetings-XBRL
-
Hester Biosciences L - Shareholders meeting
-
Hester Biosciences L has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Hester Biosciences L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Hester Biosciences L - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Hester Biosciences L - Updates
-
Hester Biosciences L - Outcome Of Resolutions Passed By The Board Of Directors By Circulation
-
Hester Biosciences L - Updates
-
Hester Biosciences L - Change Of Name Of Registrar And Share Transfer Agent (\RTA\) Of The Company
-
Hester Biosciences L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Hester Biosciences L - Resignation
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Change in Management
-
Hester Biosciences L - Trading Window-XBRL
-
Hester Biosciences L - Trading Window
-
Hester Biosciences L - Credit Rating
-
Hester Biosciences L - Announcement under Regulation 30 (LODR)-Credit Rating
-
Hester Biosciences
-
Hester acquires technology from ICAR – NIHSAD
-
Hester Biosciences gets Rs. 600 million grant to make COVID vaccine
-
Hester Biosciences forays into Pet Care sector with New Products
-
Hester Biosciences
-
Cadila, Hester Biosceinces
-
Hester signs two agreements with ICAR-IVRI
-
IIT Guwahati collaborates with Hester Biosciences
-
Hester Biosciences board to raise fund up to Rs. 150 crore
-
Hester Biosciences to invest in African subsidiary
Key fundamentals
Evaluate the intrinsic value of Hester Biosciences Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 446.276 | 456.704 | 390.347 | 241.967 | 242.326 |
Liabilities | 446.276 | 456.704 | 390.347 | 241.967 | 242.326 |
Equity | 8.507 | 8.507 | 8.507 | 8.507 | 8.507 |
Gross Profit | 47.341 | 54.886 | 60.569 | 71.993 | 52.721 |
Net Profit | 27.159 | 32.342 | 39.517 | 39.901 | 31.224 |
Cash From Operating Activities | 42.812 | 33.362 | 15.905 | 40.071 | 25.822 |
NPM(%) | 9.52 | 12.73 | 18.01 | 19.13 | 18.42 |
Revenue | 285.155 | 254 | 219.351 | 208.477 | 169.425 |
Expenses | 237.814 | 199.114 | 158.782 | 136.484 | 116.704 |
ROE(%) | 8.99 | 10.71 | 13.09 | 13.21 | 10.34 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
22 Aug 2024 | 6 | 60 | 0.44 | 1735.8 |
13 Sep 2023 | 8 | 80 | 0.44 | 1723.7 |
11 Aug 2022 | 10 | 100 | 0.44 | 2276.75 |
05 Aug 2021 | 10 | 100 | 0.44 | 2754.9 |
27 Aug 2020 | 6.6 | 66 | 0.44 | 1254 |
18 Jul 2019 | 7 | 70 | 0.44 | 1531.15 |
09 Nov 2018 | 2 | 20 | 0.44 | 1156.35 |
30 Aug 2018 | 2 | 20 | 0.44 | 1345.85 |
02 Aug 2018 | 6 | 60 | 0.44 | 1529.6 |
20 Jul 2017 | 2.3 | 23 | 0.44 | 879.2 |
03 Nov 2016 | 3 | 30 | 0.44 | 756.75 |
21 Jul 2016 | 1.1 | 11 | 0.44 | 648.05 |
17 Mar 2016 | 3 | 30 | 0.44 | 425.45 |
10 Sep 2015 | 3.1 | 31 | 0.44 | 548.4 |
Peers
Other companies within the same industry or sector that are comparable to Hester Biosciences Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 769.87 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 2805.32 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 1445.97 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 2645.17 | -239.30 | 0.00 |
Company Info
YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine
YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine
Read More
Parent Organisation
Hester Biosciences Ltd.
Founded
29/04/1987
Managing Director
Mr.Rajiv Gandhi
NSE Symbol
HESTERBIOEQ
FAQ
The current price of Hester Biosciences Ltd is ₹ 1352.40.
The 52-week high for Hester Biosciences Ltd is ₹ 1378.25 and the 52-week low is ₹ 1275.00.
The market capitalization of Hester Biosciences Ltd is currently ₹ 1150.47. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Hester Biosciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Hester Biosciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Hester Biosciences Ltd shares.
The CEO of Hester Biosciences Ltd is Mr.Rajiv Gandhi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.